Vishal Agrawal, MD
Pulmonary Disease · Dublin, GANPI 1902995178
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $945 and has fallen 85.6% since, to $136 in 2025. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 106 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$264
- Insmed, Inc.$257
- GSK$241
- Mylan Specialty L.p.$194
- Boehringer Ingelheim$166
- AstraZeneca$92
- plus $683 from 20 others
Across 6 payments — averaging $10,014 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$60K
What the payments were for
- Food & beverage$1,85498%
- Education$442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 19 | $264 |
| Insmed, Inc. | 11 | $257 |
| GSK | 16 | $241 |
| Mylan Specialty L.p. | 10 | $194 |
| Boehringer Ingelheim | 8 | $166 |
| AstraZeneca | 6 | $92 |
| Grifols USA, LLC | 6 | $92 |
| Sanofi | 2 | $71 |
| Circassia Inc. | 4 | $62 |
| Advanced Respiratory, Inc | 3 | $56 |
| Genentech USA, Inc. | 2 | $43 |
| Amgen | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Verona Pharma, Inc. | 1 | $26 |
| Johnson & Johnson | 2 | $25 |
| AbbVie | 1 | $25 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $22 |
| United Therapeutics Corporation | 1 | $22 |
| Olympus America Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Electromed, Inc. | 2 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Itamar Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$107
How this compares
$1,898 in reported general payments places this provider in the 35th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ambrisentan | 12 | $34,200 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $242 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Dublin
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.